Windfall Bio

windfall.bio →

-74%

est. 2Y upside i

Series A

Rank

#2244

Sector

Agricultural Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Windfall Bio presents a moderate upside opportunity for a job seeker, driven by its innovative methane-to-organic fertilizer technology addressing two large and growing markets.

Last updated: March 10, 2026

Bull (15%)+300%

Windfall Bio's FOUNDATION™ organic fertilizer gains significant market share due to proven superior yields (23-34% increase in trials) and OMRI certification, while its methane mitigation technology becomes a preferred solution for large dairy farms and landfills. This drives revenue to $100M+ by 2028, justifying a $480M+ valuation (4x current) as the company captures a meaningful share of the rapidly growing carbon credit market (35% CAGR).

Base (50%)+50%

Windfall Bio successfully expands pilot deployments and secures key commercial contracts in agriculture and waste management, achieving steady growth. Revenue reaches $40M-$50M by 2028, primarily from fertilizer sales and moderate carbon credit monetization. The company maintains its competitive position against traditional organic fertilizer providers and niche methane solutions, leading to an acquisition or Series B at a $180M valuation (1.5x current).

Bear (35%)-80%

Despite initial successes, Windfall Bio faces slower-than-expected adoption due to high upfront costs for bioreactor systems and strong competition from established fertilizer companies and renewable natural gas providers. Regulatory hurdles or a downturn in carbon credit prices further constrain growth. Revenue stalls at $20M-$25M by 2028, leading to a down round or distressed acquisition at a $24M valuation (0.2x current), significantly eroding common stock value due to the $37M liquidation preference.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Investors hold $37M in liquidation preferences. In an exit at or below the estimated $120M valuation, common stock holders would see returns only after this $37M is paid out.

Dilution Risk

moderate

As a Series A company, Windfall Bio will likely require additional funding rounds, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

Windfall Bio is a private company with low market activity; there are currently no active buyers or sellers of its stock in secondary markets.

Questions to Ask at the Interview

Strategic questions based on Windfall Bio's data — designed to show you've done your homework.

  • 1

    “Given the significant growth projected for the carbon credit market (35% CAGR), how does Windfall Bio plan to maximize its monetization strategy for carbon credits, especially considering past market stagnation?”

  • 2

    “With large agricultural chemical companies and RNG providers posing a medium incumbent threat, what specific strategies are in place to defend and expand market share for FOUNDATION™ fertilizer and the methane mitigation solution?”

  • 3

    “Considering the $37M in liquidation preferences, what is the company's realistic timeline and strategy for a liquidity event that would provide meaningful returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -74% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.